MBM Wealth Consultants LLC Has $775,000 Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

MBM Wealth Consultants LLC raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 1.9% in the 4th quarter, HoldingsChannel reports. The fund owned 2,151 shares of the biotechnology company’s stock after buying an additional 41 shares during the quarter. MBM Wealth Consultants LLC’s holdings in United Therapeutics were worth $775,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of UTHR. JPMorgan Chase & Co. increased its holdings in shares of United Therapeutics by 35.4% in the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after purchasing an additional 50,291 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares during the period. Burney Co. lifted its stake in United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after buying an additional 12,705 shares during the period. Bridgewater Associates LP boosted its stake in United Therapeutics by 384.3% during the 3rd quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock worth $22,130,000 after acquiring an additional 49,003 shares during the last quarter. Finally, Glenmede Trust Co. NA boosted its position in shares of United Therapeutics by 6.4% during the third quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock worth $24,585,000 after purchasing an additional 4,145 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 14,700 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $964,983.42. The trade was a 85.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Edgemond sold 7,800 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the sale, the chief financial officer now directly owns 6,978 shares in the company, valued at $2,442,300. This trade represents a 52.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 136,848 shares of company stock valued at $51,515,999 in the last three months. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

UTHR stock opened at $367.97 on Wednesday. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The stock has a market capitalization of $16.43 billion, a price-to-earnings ratio of 16.16, a PEG ratio of 0.92 and a beta of 0.57. The business’s fifty day moving average price is $365.91 and its two-hundred day moving average price is $355.01.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the previous year, the company earned $5.38 EPS. The business’s revenue was up 22.9% on a year-over-year basis. Research analysts expect that United Therapeutics Co. will post 25.22 EPS for the current year.

Analyst Ratings Changes

UTHR has been the topic of several recent analyst reports. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright raised their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH lifted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.